Therapeutic interventions target the NLRP3 inflammasome in ulcerative colitis: Comprehensive study

World J Gastroenterol. 2023 Feb 14;29(6):1026-1053. doi: 10.3748/wjg.v29.i6.1026.

Abstract

One of the significant health issues in the world is the prevalence of ulcerative colitis (UC). UC is a chronic disorder that mainly affects the colon, beginning with the rectum, and can progress from asymptomatic mild inflammation to extensive inflammation of the entire colon. Understanding the underlying molecular mechanisms of UC pathogenesis emphasizes the need for innovative therapeutic approaches based on identifying molecular targets. Interestingly, in response to cellular injury, the NLR family pyrin domain containing 3 (NLRP3) inflammasome is a crucial part of the inflammation and immunological reaction by promoting caspase-1 activation and the release of interleukin-1β. This review discusses the mechanisms of NLRP3 inflammasome activation by various signals and its regulation and impact on UC.

Keywords: NLR family pyrin domain containing 3 inflammasome; Phytochemicals; Probiotics; Therapeutic strategies; Ulcerative colitis.

Publication types

  • Review

MeSH terms

  • Colitis*
  • Colitis, Ulcerative* / drug therapy
  • Humans
  • Inflammasomes
  • Inflammation
  • NLR Family, Pyrin Domain-Containing 3 Protein

Substances

  • Inflammasomes
  • NLR Family, Pyrin Domain-Containing 3 Protein